Equillium Past Earnings Performance

Past criteria checks 0/6

Equillium has been growing earnings at an average annual rate of 9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 76.9% per year.

Key information

9.0%

Earnings growth rate

21.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate76.9%
Return on equity-19.9%
Net Margin-10.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

Nov 16
Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop

Sep 26
Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop

Benign Growth For Equillium, Inc. (NASDAQ:EQ) Underpins Stock's 54% Plummet

Jun 16
Benign Growth For Equillium, Inc. (NASDAQ:EQ) Underpins Stock's 54% Plummet

We Think Equillium (NASDAQ:EQ) Needs To Drive Business Growth Carefully

May 01
We Think Equillium (NASDAQ:EQ) Needs To Drive Business Growth Carefully

Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

Mar 27
Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Aug 14
Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Aug 12
Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

May 03
Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Mar 26
Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Equillium GAAP EPS of -$0.41 in-line

Aug 15

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Oct 08

Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Mar 09
Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Equillium prices $30M registered direct offering

Feb 04

Equillium (EQ) Investor Presentation - Slideshow

Dec 04

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

Nov 24
How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

FDA gives green signal to Equillium's late-stage COVID-19 trial

Oct 30

Revenue & Expenses Breakdown

How Equillium makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:EQ Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2446-51339
30 Jun 2443-81439
31 Mar 2438-121438
31 Dec 2336-131437
30 Sep 2343-81636
30 Jun 2334-181636
31 Mar 2325-291736
31 Dec 2216-621738
30 Sep 220-761537
30 Jun 220-721335
31 Mar 220-671231
31 Dec 210-391126
30 Sep 210-371125
30 Jun 210-341023
31 Mar 210-311021
31 Dec 200-301019
30 Sep 200-281018
30 Jun 200-281018
31 Mar 200-27919
31 Dec 190-26918
30 Sep 190-23915
30 Jun 190-22712
31 Mar 190-1868
31 Dec 180-1345
30 Sep 180-1023

Quality Earnings: EQ is currently unprofitable.

Growing Profit Margin: EQ is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EQ is unprofitable, but has reduced losses over the past 5 years at a rate of 9% per year.

Accelerating Growth: Unable to compare EQ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: EQ has a negative Return on Equity (-19.91%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Equillium, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lut Ming ChengCantor Fitzgerald & Co.
Raghuram SelvarajuH.C. Wainwright & Co.
Biren AminJefferies LLC